Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...

Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Start 7-day free trial → Log in

Ibezapolstat · ACX-362E

Small molecule · developed by Acurx Pharmaceuticals

Phase 2 Most advanced trial

ACXP Developer

1 Registered trials

What is Ibezapolstat?

Ibezapolstat (ACX-362E) is a small-molecule oral agent studied in Clostridium difficile infection recurrence.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as: ACX-362E
Drug type: Small molecule
Therapy area: Infectious disease
Developer: Acurx Pharmaceuticals Inc. (ACXP)
FDA status: Investigational, not approved in the US. Most advanced trial: Phase 2
UNII: 5K543KNC5P

🧪 Clinical trials

Trial	Phase	Condition	Status	Sponsor
NCT07513285	Phase 2	Clostridium Difficile Infection Recurrence	Recruiting	ACXP

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Clostridium Difficile Infection Recurrence

Sources

ClinicalTrials.gov NCT07513285

Updated Oct 3, 2026. Something wrong or missing? Report it on the ACXP page.

Follow ACXP, the company behind Ibezapolstat

See ACXP's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

ACXP catalysts and pipeline →

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z